世界卫生组织与几内亚卫生部及国际合作机构将于2015年3月7日在几内亚巴塞地区启动VSV-EBOV埃博拉疫苗的第三期临床试验1。这项试验旨在测试该疫苗的有效性和安全性，采用环形接种策略，将对确诊患者的接触者进行接种1。该接种方法基于1970年代天花根除的经验1。
VSV-EBOV疫苗由加拿大公共卫生署开发1。全球疫苗联盟已于2014年12月批准为该疫苗提供3亿美元资金支持，另有9000万美元用于疫苗部署1。无国界医生组织和挪威公共卫生研究所等机构参与了合作1。WHO总干事玛格丽特·陈表示："如果疫苗被证实有效，它将成为人类历史上首个埃博拉预防工具"1。
The World Health Organization, in collaboration with Guinea's Ministry of Health and international partners including Médecins Sans Frontières and the Norwegian Institute of Public Health, is set to begin a Phase III clinical trial of the VSV-EBOV Ebola vaccine on March 7, 2015, in the Basse region of Guinea.1 The vaccine, developed by the Public Health Agency of Canada, will be tested using a ring vaccination strategy modeled on the smallpox eradication campaigns of the 1970s, with initial immunizations administered to contacts of confirmed Ebola cases in the hardest-hit areas.1
The trial represents a critical step toward developing the first preventive tool against Ebola in human history.1 The Global Alliance for Vaccines and Immunization approved $300 million in funding for the initiative in December 2014, with an additional $90 million allocated for vaccine deployment.1 According to WHO Director-General Margaret Chan, if the vaccine proves effective, "it will become the first Ebola prevention tool in human history."1
评论
还没有评论，欢迎留下第一条。